myNEO Therapeutics is extremely excited to announce the publication in the Cancer Cell journal, written by myNEO Therapeutics colleagues Lien, Steve, and Bruno together with key pioneers in personalized immunotherapy Patrick Ott, Sjoerd van der Burg, Kris Thielemans, Wim Van Criekinge, Steven Feldman, Luc Dirix, Karine Breckpot, Bruno De Geest, and Evelien Smits.

Neoantigen-directed therapy is a promising strategy; however, several roadblocks lie ahead. We provide an in-depth overview of the current state of the field with an emphasis on the neoantigen discovery and different clinical aspects that need to be addressed to unlock the full potential of this therapy for the patients.